BioMarin Pharmaceutical Inc.
BMRNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States,. Valued at $12.51B, BMRN is a large-cap name in its sector. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.
Market Cap
$12.51B
Beta
0.24
P/E (TTM)
174.68
P/E (Fwd)
9.89
EPS (TTM)
$0.37
EPS (Fwd)
$6.54
ROE
1.2%
ROA
3.3%
Cash
$874.0M
Total Debt
$4.20B
Free CF
$85.2M
52W Change
22.1%
Annual Financials
Cash vs Debt
Where BMRN stands vs its 150-day and 200-day moving averages
As of the August 27, 2026 close, BMRN finished 13.16% above its 150-day moving average ($57.98) and 14.22% above its 200-day moving average ($57.44). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BMRN overbought or oversold?
At the August 27, 2026 close, BMRN's RSI(14) was 59.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $874.0M in cash, though total debt stands at $4.20B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $85.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 1.2% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.3% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $2.10B (2022) to $3.22B (2025), reflecting a 54% increase over the period.
The relatively low beta of 0.24 suggests BMRN is a less volatile holding compared to the broader index. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence BioMarin Pharmaceutical Inc.'s trajectory.